Clinical trial
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in…
NCT02853331 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT02853331 |
|---|---|
| Title | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) |
| Official title | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Biological, Drug |
| Interventions | Pembrolizumab, Axitinib, Sunitinib |
| Enrollment | 861 |
| Start date | Sep 16, 2016 |
| Primary completion | Oct 18, 2018 |
| Completion | Dec 26, 2025 |
| First posted | Aug 2, 2016 |
| Last update posted | Feb 2, 2026 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: